ID: ALA83279

Max Phase: Preclinical

Molecular Formula: C26H27N3O

Molecular Weight: 397.52

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  c1ccc(-n2cnc3cc(-c4ccc(OCCN5CCCCC5)cc4)ccc32)cc1

Standard InChI:  InChI=1S/C26H27N3O/c1-3-7-23(8-4-1)29-20-27-25-19-22(11-14-26(25)29)21-9-12-24(13-10-21)30-18-17-28-15-5-2-6-16-28/h1,3-4,7-14,19-20H,2,5-6,15-18H2

Standard InChI Key:  PNGUVNHPACPGIY-UHFFFAOYSA-N

Associated Targets(Human)

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HUVEC 11049 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) 27 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 2 and 3 (KDR and Flt-4) 23 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VEGF-receptor 2 and PDGF-receptor beta (KDR and PDGFR beta) 29 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VEGF-receptor 2 and Fibroblast growth factor receptor 1 50 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VEGF-receptor 2 and Fibroblast growth factor receptor 2 15 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

VEGF-receptor 2 and tyrosine-protein kinase SRC 25 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus 775804 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Canis familiaris 36305 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 397.52Molecular Weight (Monoisotopic): 397.2154AlogP: 5.56#Rotatable Bonds: 6
Polar Surface Area: 30.29Molecular Species: BASEHBA: 4HBD: 0
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 8.83CX LogP: 5.50CX LogD: 4.06
Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.43Np Likeness Score: -1.34

References

1. Bilodeau MT, Cunningham AM, Koester TJ, Ciecko PA, Coll KE, Huckle WR, Hungate RW, Kendall RL, McFall RC, Mao X, Rutledge RZ, Thomas KA..  (2003)  Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.,  13  (15): [PMID:12852948] [10.1016/s0960-894x(03)00485-2]

Source